Laporan Laba Rugi (TTM)
Laporan Laba Rugi Barinthus Biotherapeutics plc - Depositary Receipt (Common Stock) menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.
Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.
|
2020 12-31 |
2021 03-31 |
2021 06-30 |
2021 09-30 |
2021 12-31 |
2022 03-31 |
2022 06-30 |
2022 09-30 |
2022 12-31 |
2023 03-31 |
2023 06-30 |
2023 09-30 |
2023 12-31 |
2024 03-31 |
2024 06-30 |
2024 09-30 |
2024 12-31 |
2025 03-31 |
2025 06-30 |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5 | 4 | 4 | 1 | 0 | 15 | 32 | 38 | 45 | 30 | 13 | 7 | 1 | 0 | 0 | 15 | 15 | 15 | 15 |
| Change (%) | -10.16 | -10.99 | -83.84 | -56.98 | 5,523.51 | 112.99 | 19.15 | 16.89 | -32.55 | -55.48 | -45.93 | -88.95 | -58.35 | -100.00 | ∞ | 0.00 | 0.00 | 0.00 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | |
| Cost Of Sales | 14 | 15 | 15 | 16 | 20 | 26 | 32 | 37 | 42 | 41 | 24 | 14 | 2 | 3 | 1 | 45 | 2 | -1 | 1 |
| Change (%) | 2.26 | 4.59 | 4.35 | 26.87 | 28.44 | 21.05 | 16.96 | 14.32 | -2.17 | -41.89 | -43.57 | -85.20 | 64.25 | -67.24 | 4,066.82 | -96.27 | -165.48 | -148.18 | |
| % of Revenue | 298.42 | 339.69 | 399.14 | 2,577.21 | 7,601.12 | 173.61 | 98.67 | 96.86 | 94.74 | 137.41 | 179.34 | 187.15 | 250.75 | 988.92 | 301.19 | 11.22 | -7.35 | 3.54 | |
| Gross Operating Profit | -10 | -10 | -12 | -15 | -20 | -11 | 0 | 1 | 2 | -11 | -11 | -6 | -1 | -3 | -1 | -30 | 13 | 16 | 14 |
| Change (%) | 8.52 | 11.09 | 33.83 | 30.26 | -44.81 | -103.84 | 181.46 | 96.25 | -579.35 | -5.57 | -40.61 | -80.89 | 145.57 | -63.56 | 2,683.36 | -144.13 | 20.92 | -10.14 | |
| % of Revenue | -198.42 | -239.69 | -299.14 | -2,477.21 | -7,501.12 | -73.61 | 1.33 | 3.14 | 5.26 | -37.41 | -79.34 | -87.15 | -150.75 | -888.92 | -201.19 | 88.78 | 107.35 | 96.46 | |
| SG&A | 10 | 11 | 23 | 23 | 25 | 27 | 8 | -4 | 6 | 15 | 35 | 47 | 40 | 34 | 28 | 41 | 24 | 30 | 38 |
| Change (%) | 6.76 | 101.52 | 0.92 | 10.39 | 8.69 | -70.01 | -150.42 | -256.66 | 131.53 | 130.51 | 34.83 | -14.50 | -15.39 | -17.66 | 46.29 | -41.93 | 27.99 | 27.34 | |
| % of Revenue | 217.38 | 258.32 | 584.85 | 3,652.17 | 9,372.39 | 181.15 | 25.51 | -10.79 | 14.47 | 49.66 | 257.11 | 641.08 | 4,960.97 | 10,078.44 | 270.87 | 157.29 | 201.31 | 256.34 | |
| R&D | -3 | -4 | -4 | -3 | -4 | -4 | -4 | -2 | -1 | -1 | 20 | 34 | 39 | 40 | 40 | -7 | 37 | 37 | 31 |
| Change (%) | 7.84 | 5.54 | -17.50 | 29.94 | 2.32 | -1.20 | -41.61 | -47.50 | 8.79 | -1,592.14 | 69.36 | 15.58 | 1.43 | 0.56 | -117.97 | -606.48 | 0.80 | -16.39 | |
| % of Revenue | -68.01 | -81.64 | -96.81 | -494.22 | -1,492.91 | -27.16 | -12.60 | -6.18 | -2.77 | -4.47 | 149.95 | 469.62 | 4,912.97 | 11,965.57 | -48.24 | 244.32 | 246.28 | 205.91 | |
| OpEx | 22 | 22 | 34 | 36 | 41 | 49 | 36 | 31 | 48 | 55 | 79 | 94 | 81 | 77 | 68 | 77 | 61 | 65 | 69 |
| Change (%) | 3.59 | 52.93 | 4.47 | 16.12 | 19.00 | -27.46 | -14.69 | 55.70 | 15.72 | 42.98 | 19.68 | -13.81 | -5.26 | -11.33 | 13.51 | -21.70 | 6.73 | 6.63 | |
| % of Revenue | 447.79 | 516.37 | 887.19 | 5,735.15 | 15,480.60 | 327.60 | 111.58 | 79.90 | 106.43 | 182.59 | 586.40 | 1,297.85 | 10,124.69 | 23,031.44 | 517.20 | 404.98 | 432.22 | 460.87 | |
| Operating Income | -17 | -18 | -30 | -35 | -41 | -34 | -4 | 8 | -3 | -25 | -65 | -87 | -80 | -77 | -68 | -62 | -46 | -50 | -54 |
| Change (%) | 7.55 | 68.28 | 15.69 | 17.41 | -16.79 | -89.16 | -306.86 | -137.38 | 766.49 | 162.20 | 33.17 | -7.54 | -4.74 | -10.95 | -8.44 | -26.90 | 8.93 | 8.62 | |
| % of Revenue | -347.79 | -416.37 | -787.19 | -5,635.15 | -15,380.60 | -227.60 | -11.58 | 20.10 | -6.43 | -82.59 | -486.40 | -1,197.85 | -10,024.69 | -22,931.44 | -417.20 | -304.98 | -332.22 | -360.87 | |
| Interest Expense | -4 | -6 | -6 | -5 | -3 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | |
| Change (%) | 73.61 | -0.00 | -15.50 | -49.48 | -96.55 | -71.74 | -30.77 | 5.56 | 60.00 | -30.00 | 42.86 | -5.00 | 26.32 | 10.42 | 1.89 | -0.00 | |||
| % of Revenue | -74.67 | -144.31 | -162.13 | -847.67 | -995.52 | -0.61 | -0.08 | -0.05 | -0.04 | -0.19 | -0.55 | -3.49 | -11.98 | -0.32 | -0.35 | -0.36 | -0.36 | ||
| Net Income | -18 | -29 | -41 | -46 | -51 | -33 | -1 | 11 | 5 | -15 | -55 | -77 | -73 | -71 | -64 | -58 | -61 | -65 | -69 |
| Change (%) | 64.65 | 42.32 | 11.36 | 10.08 | -35.12 | -95.82 | -926.79 | -53.21 | -388.92 | 255.90 | 40.62 | -5.04 | -3.67 | -9.72 | -9.34 | 5.62 | 6.81 | 6.43 | |
| % of Revenue | -367.27 | -673.12 | -1,076.32 | -7,416.85 | -18,979.48 | -218.97 | -4.30 | 29.85 | 11.95 | -51.19 | -409.19 | -1,064.10 | -9,145.51 | -21,154.49 | -386.31 | -408.00 | -435.79 | -463.80 | |
Source: Capital IQ
